Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Torsemide

×

Overview

What is Torsemide?

Torsemide is a diuretic of the pyridine-sulfonylurea class. Its chemical name is 1-isopropyl-3-[(4--toluidino-3-pyridyl) sulfonyl] urea and its structural formula is:

Its molecular formula is CHNOS, its pKa is 7.1, and its molecular weight is 348.43.

Torsemide USP is a white to off-white crystalline powder. The tablets for oral administration also contain crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone.



What does Torsemide look like?



What are the available doses of Torsemide?

Tablets:  5 mg, 10 mg, 20 mg and 100 mg ()

What should I talk to my health care provider before I take Torsemide?

How should I use Torsemide?

Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease.

Edema associated with heart failure

The recommended initial dose is 10 mg or 20 mg oral torsemide tablets once daily. If the diuretic response is inadequate, titrate upward by approximately doubling until the desired diuretic response is obtained. Doses higher than 200 mg have not been adequately studied.

Edema associated with chronic renal failure

The recommended initial dose is 20 mg oral torsemide tablets once daily. If the diuretic response is inadequate, titrate upward by approximately doubling until the desired diuretic response is obtained. Doses higher than 200 mg have not been adequately studied.

Edema associated with hepatic cirrhosis

The recommended initial dose is 5 mg or 10 mg oral torsemide tablets once daily, administered together with an aldosterone antagonist or a potassium-sparing diuretic. If the diuretic response is inadequate, titrate upward by approximately doubling until the desired diuretic response is obtained. Doses higher than 40 mg have not been adequately studied in this population.


What interacts with Torsemide?

Sorry No Records found


What are the warnings of Torsemide?

Sorry No Records found


What are the precautions of Torsemide?

Sorry No Records found


What are the side effects of Torsemide?

Sorry No records found


What should I look out for while using Torsemide?

Torsemide tablets are contraindicated in patients with known hypersensitivity to torsemide or to povidone.

Torsemide tablets are contraindicated in patients who are anuric. Torsemide tablets are contraindicated in patients with hepatic coma.


What might happen if I take too much Torsemide?

The signs and symptoms of overdosage can be anticipated to include those of excessive pharmacologic effect: dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Treatment of overdosage should consist of fluid and electrolyte replacement.

Laboratory determinations of serum levels of torsemide and its metabolites are not widely available.

No data are available to suggest physiological maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of torsemide and its metabolites. Torsemide is not dialyzable, so hemodialysis will not accelerate elimination.


How should I store and handle Torsemide?

StorageStore Pantoprazole Sodium Delayed-Release Tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [ ]. StorageStore Pantoprazole Sodium Delayed-Release Tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [ ]. Torsemide Tablets USP 5 mgBottles of 100                       NDC 57237-138-01Torsemide Tablets USP 10 mgBottles of 100                       NDC 57237-139-01Torsemide Tablets USP 20 mgBottles of 100                       NDC 57237-140-01Torsemide Tablets USP 100 mgBottles of 100                       NDC 57237-141-01Store atTorsemide Tablets USP 5 mgBottles of 100                       NDC 57237-138-01Torsemide Tablets USP 10 mgBottles of 100                       NDC 57237-139-01Torsemide Tablets USP 20 mgBottles of 100                       NDC 57237-140-01Torsemide Tablets USP 100 mgBottles of 100                       NDC 57237-141-01Store atTorsemide Tablets USP 5 mgBottles of 100                       NDC 57237-138-01Torsemide Tablets USP 10 mgBottles of 100                       NDC 57237-139-01Torsemide Tablets USP 20 mgBottles of 100                       NDC 57237-140-01Torsemide Tablets USP 100 mgBottles of 100                       NDC 57237-141-01Store atTorsemide Tablets USP 5 mgBottles of 100                       NDC 57237-138-01Torsemide Tablets USP 10 mgBottles of 100                       NDC 57237-139-01Torsemide Tablets USP 20 mgBottles of 100                       NDC 57237-140-01Torsemide Tablets USP 100 mgBottles of 100                       NDC 57237-141-01Store atTorsemide Tablets USP 5 mgBottles of 100                       NDC 57237-138-01Torsemide Tablets USP 10 mgBottles of 100                       NDC 57237-139-01Torsemide Tablets USP 20 mgBottles of 100                       NDC 57237-140-01Torsemide Tablets USP 100 mgBottles of 100                       NDC 57237-141-01Store atTorsemide Tablets USP 5 mgBottles of 100                       NDC 57237-138-01Torsemide Tablets USP 10 mgBottles of 100                       NDC 57237-139-01Torsemide Tablets USP 20 mgBottles of 100                       NDC 57237-140-01Torsemide Tablets USP 100 mgBottles of 100                       NDC 57237-141-01Store atTorsemide Tablets USP 5 mgBottles of 100                       NDC 57237-138-01Torsemide Tablets USP 10 mgBottles of 100                       NDC 57237-139-01Torsemide Tablets USP 20 mgBottles of 100                       NDC 57237-140-01Torsemide Tablets USP 100 mgBottles of 100                       NDC 57237-141-01Store atTorsemide Tablets USP 5 mgBottles of 100                       NDC 57237-138-01Torsemide Tablets USP 10 mgBottles of 100                       NDC 57237-139-01Torsemide Tablets USP 20 mgBottles of 100                       NDC 57237-140-01Torsemide Tablets USP 100 mgBottles of 100                       NDC 57237-141-01Store atTorsemide Tablets USP 5 mgBottles of 100                       NDC 57237-138-01Torsemide Tablets USP 10 mgBottles of 100                       NDC 57237-139-01Torsemide Tablets USP 20 mgBottles of 100                       NDC 57237-140-01Torsemide Tablets USP 100 mgBottles of 100                       NDC 57237-141-01Store at


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na/K/2Cl-carrier system. Clinical pharmacology studies have confirmed this site of action in humans, and effects in other segments of the nephron have not been demonstrated. Diuretic activity thus correlates better with the rate of drug excretion in the urine than with the concentration in the blood.

Torsemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance.

Non-Clinical Toxicology
Torsemide tablets are contraindicated in patients with known hypersensitivity to torsemide or to povidone.

Torsemide tablets are contraindicated in patients who are anuric. Torsemide tablets are contraindicated in patients with hepatic coma.

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Absorption of tetracyclines is impaired by bismuth subsalicylate.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.

Concurrent use of tetracycline may render oral contraceptives less effective.

Excessive diuresis may cause potentially symptomatic dehydration, blood volume reduction and hypotension and worsening renal function, including acute renal failure particularly in salt-depleted patients or those taking renin-angiotensin aldosterone inhibitors. Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). Monitor volume status and renal function periodically.

The following risks are discussed in more detail in others sections:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).